Headquartered in Edison, New Jersey, MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. The company provides safe, high-quality tissue grafts from donated human tissues that are used in a growing array of clinical fields, including orthopedics, plastic and reconstructive surgery, wound care, and regenerative medicine.
MTF is exploring disruptive science and technologies which might benefit from the use of human tissue and their associated natural biological properties while continuing to generate scientific and clinical evidence to support the regenerative potential of human allograft tissues.
International Institute for the Advancement of Medicine (IIAM), a division of MTF Biologics, provides non-transplantable organs and tissues to the medical research community for purposes of combatting and curing disease. IIAM has unprecedented collaborations in the U.S. to source livers and other organs for groundbreaking medical studies, therapeutic applications and pre-clinical investigations targeting a range of debilitating metabolic disorders. As a nonprofit with more than 30 years of experience in the field, IIAM is a known and trusted partner to both organ procurement organizations and research institutions worldwide. IIAM works closely with them to honor donor and donor family intentions to the fullest by anticipating the next frontier of research requiring human tissue. IIAM leads the way in educating the next generation of researchers so that every donor’s legacy leaves the world a healthier place.
“ARMI | BioFabUSA provides a forum for collaboration and sharing of ideas and fosters a synergistic environment to accelerate time to market and patient for new technologies,” said Marc Long, PhD, Executive VP of R&D at MTF.
Working with every organ procurement organization in the country, IIAM screens over 27,000 non-transplantable organs authorized for medical research and development. “It is our greatest hope that our membership with ARMI will identify new partners engaged in studies requiring human tissue, making the greatest use of the donor gift through this rare resource,” said Gina Dunne Smith, Executive Director of IIAM.
Smith went on to say that IIAM has developed an impressive network within the donation and medical research community. “Over the past 34 years, we have become the leading provider of viable, non-transplantable human organs and tissues providing this precious biomaterial to scientists involved in nearly every aspect of groundbreaking medical research and therapeutic development,” Smith said. “We come to ARMI as a subject matter expert in organ and tissue donation for use in the advancement of medicine and technology.”
Long believes breakthroughs in regenerative medicine over the next 5 – 10 years will involve the use of stem cells as a therapeutic and healing agent; decell/recell organs, tissues and VCAs; organ preservation using normothermic and cryo technology.
“MTF Biologics and IIAM have the unique opportunity to provide the designed and optimized by nature organ and tissue biologic materials to support and accelerate the advancement fo regenerative medicine. We look forward to being a part of this picture as we provide the needed biomaterial to achieve these great goals or saving and healing more lives,” said Long.
